|Therapeutic Candidate||Target||Trial Link||Trial Description|
A study to evaluate the safety and tolerability of DKN-01 in combination with weekly paclitaxel in participants with refractory/recurrent esophageal, gastro-esophageal junction and gastric cancer
Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder
A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Relapsed/Refractory Endometrioid Endometrial or Endometrioid Ovarian Cancer
|TRX518||GITR||NCT01239134||Study of TRX518 in Stage III or IV Malignant Melanoma or Other Solid Tumors|
|TRX518||GITR||NCT02628574||Dose Escalation Study of TRX518 in Adults With Advanced Solid Tumors|
Translating Cancer Research to Patients
Leap Therapeutics’ current clinical program includes product candidates targeting esophagogastric cancer, gynecologic cancer, biliary tract cancer, and other solid tumor malignancies. Details on our clinical trials are summarized below.